Literature DB >> 26261602

The potential of plasma miRNAs for diagnosis and risk estimation of colorectal cancer.

Wang-Yang Chen1, Xiao-Juan Zhao1, Zhi-Fu Yu1, Fu-Lan Hu1, Yu-Peng Liu1, Bin-Bin Cui2, Xin-Shu Dong3, Ya-Shuang Zhao1.   

Abstract

Circulating microRNAs (miRNAs) were recognized to be potential non-invasive biomarkers for colorectal cancer (CRC) detection and prediction. Meanwhile, the association of the expression of plasma miRNAs with the risk of CRC patients has rarely been analyzed. Therefore, we conducted this study to evaluate the value of plasma miRNAs for CRC diagnosis and risk estimation. Fasting blood samples from 100 CRC patients and 79 cancer-free controls were collected. Plasma miR-106a, miR-20a, miR-27b, miR-92a and miR-29a levels were detected by RT-qPCR. Sensitivity and specificity were employed to evaluate the diagnostic value of miRNAs for CRC. Univariate and multivariate logistic regression were employed to analyze the association between miRNAs expression and CRC risk. As results, miR-106a and miR-20a were elevated in the patients with CRC. The sensitivity of miR-106a was 74.00% and the specificity was 44.40%, while the cutoff value was 2.03. As for miR-20a, the sensitivity was 46.00% and specificity was 73.42% when employed 2.44 as cutoff value. High expression of plasma miR-106a increased CRC risk by 1.80 -fold. Plasma miR-106a and miR-20a may as noninvasive biomarkers for detecting the CRC. High expression of miR-106a associated with CRC risk.

Entities:  

Keywords:  colorectal cancer; diagnosis; microRNA; plasma; risk factor

Mesh:

Substances:

Year:  2015        PMID: 26261602      PMCID: PMC4525936     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  46 in total

1.  Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients.

Authors:  Jianning Song; Zhigang Bai; Wei Han; Jun Zhang; Hua Meng; Jintao Bi; Xuemei Ma; Shiwei Han; Zhongtao Zhang
Journal:  Dig Dis Sci       Date:  2011-12-25       Impact factor: 3.199

2.  Fecal miR-106a is a useful marker for colorectal cancer patients with false-negative results in immunochemical fecal occult blood test.

Authors:  Yoshikatsu Koga; Nobuyoshi Yamazaki; Yoshiyuki Yamamoto; Seiichiro Yamamoto; Norio Saito; Yasuo Kakugawa; Yosuke Otake; Minori Matsumoto; Yasuhiro Matsumura
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-08-15       Impact factor: 4.254

3.  Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma.

Authors:  Cheng Fang; Dan-Xia Zhu; Hua-Jie Dong; Zhi-Jian Zhou; Yin-Hua Wang; Ling Liu; Lei Fan; Kou-Rong Miao; Peng Liu; Wei Xu; Jian-Yong Li
Journal:  Ann Hematol       Date:  2011-10-11       Impact factor: 3.673

4.  HIF-1α downregulates miR-17/20a directly targeting p21 and STAT3: a role in myeloid leukemic cell differentiation.

Authors:  M He; Q-Y Wang; Q-Q Yin; J Tang; Y Lu; C-X Zhou; C-W Duan; D-L Hong; T Tanaka; G-Q Chen; Q Zhao
Journal:  Cell Death Differ       Date:  2012-10-12       Impact factor: 15.828

5.  Colorectal cancer mass-screening: estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time.

Authors:  G Launoy; T C Smith; S W Duffy; V Bouvier
Journal:  Int J Cancer       Date:  1997-10-09       Impact factor: 7.396

6.  Alteration of serum miR-206 and miR-133b is associated with lung carcinogenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.

Authors:  Jianjun Wu; Ti Yang; Xun Li; Qiaoyuan Yang; Rong Liu; Jinkun Huang; Yuanqi Li; Chengfeng Yang; Yiguo Jiang
Journal:  Toxicol Appl Pharmacol       Date:  2013-01-18       Impact factor: 4.219

7.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.

Authors:  Aaron J Schetter; Suet Yi Leung; Jane J Sohn; Krista A Zanetti; Elise D Bowman; Nozomu Yanaihara; Siu Tsan Yuen; Tsun Leung Chan; Dora L W Kwong; Gordon K H Au; Chang-Gong Liu; George A Calin; Carlo M Croce; Curtis C Harris
Journal:  JAMA       Date:  2008-01-30       Impact factor: 56.272

8.  Computed tomographic colonography to screen for colorectal cancer, extracolonic cancer, and aortic aneurysm: model simulation with cost-effectiveness analysis.

Authors:  Cesare Hassan; Perry J Pickhardt; Perry Pickhardt; Andrea Laghi; Daniel H Kim; Daniel Kim; Angelo Zullo; Franco Iafrate; Lorenzo Di Giulio; Sergio Morini
Journal:  Arch Intern Med       Date:  2008-04-14

9.  Increased circulating microRNA-155 as a potential biomarker for breast cancer screening: a meta-analysis.

Authors:  Faliang Wang; Jinchao Hou; Wei Jin; Jiaqiu Li; Yongfang Yue; Hongchuan Jin; Xian Wang
Journal:  Molecules       Date:  2014-05-16       Impact factor: 4.411

10.  Interaction of Serum microRNAs and Serum Folate With the Susceptibility to Pancreatic Cancer.

Authors:  Yao Tian; Yibo Xue; Gechong Ruan; Kailiang Cheng; Jing Tian; Qian Qiu; Min Xiao; Hui Li; Hong Yang; Li Wang
Journal:  Pancreas       Date:  2015-01       Impact factor: 3.327

View more
  19 in total

1.  MicroRNAs as potential liquid biopsy biomarkers in colorectal cancer: A systematic review.

Authors:  Yuji Toiyama; Yoshinaga Okugawa; James Fleshman; C Richard Boland; Ajay Goel
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-05-29       Impact factor: 10.680

2.  miR-106a suppresses tumor cells death in colorectal cancer through targeting ATG7.

Authors:  Haibin Hao; Guangfeng Xia; Chao Wang; Fuping Zhong; Laipeng Liu; Dong Zhang
Journal:  Med Mol Morphol       Date:  2016-12-15       Impact factor: 2.309

3.  Targeting the lipid metabolic axis ACSL/SCD in colorectal cancer progression by therapeutic miRNAs: miR-19b-1 role.

Authors:  Silvia Cruz-Gil; Ruth Sanchez-Martinez; Marta Gomez de Cedron; Roberto Martin-Hernandez; Teodoro Vargas; Susana Molina; Jesús Herranz; Alberto Davalos; Guillermo Reglero; Ana Ramirez de Molina
Journal:  J Lipid Res       Date:  2017-10-26       Impact factor: 5.922

4.  Expression of Circulating miR-155, miR-21, miR-221, miR-30a, miR-34a and miR-29a: Comparison of Colonic and Rectal Cancer.

Authors:  Enikő Orosz; István Kiss; Zoltán Gyöngyi; Tímea Varjas
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

5.  MicroRNA-20a in human faeces as a non-invasive biomarker for colorectal cancer.

Authors:  Tung On Yau; Chung Wah Wu; Ceen-Ming Tang; Yingxuan Chen; Jingyuan Fang; Yujuan Dong; Qiaoyi Liang; Simon Siu Man Ng; Francis Ka Leung Chan; Joseph Jao Yiu Sung; Jun Yu
Journal:  Oncotarget       Date:  2016-01-12

Review 6.  Methods and novel technology for microRNA quantification in colorectal cancer screening.

Authors:  Laura Moody; Hongshan He; Yuan-Xiang Pan; Hong Chen
Journal:  Clin Epigenetics       Date:  2017-10-24       Impact factor: 6.551

7.  Peroxisome Proliferator-Activated Receptor Gamma in Obesity and Colorectal Cancer: the Role of Epigenetics.

Authors:  T K Motawi; O G Shaker; M F Ismail; N H Sayed
Journal:  Sci Rep       Date:  2017-09-06       Impact factor: 4.379

Review 8.  Updates on Clinical Use of Liquid Biopsy in Colorectal Cancer Screening, Diagnosis, Follow-Up, and Treatment Guidance.

Authors:  Omayma Mazouji; Abdelhak Ouhajjou; Roberto Incitti; Hicham Mansour
Journal:  Front Cell Dev Biol       Date:  2021-05-24

Review 9.  New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies.

Authors:  Erika Larrea; Carla Sole; Lorea Manterola; Ibai Goicoechea; María Armesto; María Arestin; María M Caffarel; Angela M Araujo; María Araiz; Marta Fernandez-Mercado; Charles H Lawrie
Journal:  Int J Mol Sci       Date:  2016-04-27       Impact factor: 5.923

10.  A three-microRNA signature for lung squamous cell carcinoma diagnosis in Chinese male patients.

Authors:  Lan Zhang; Xia Shan; Jun Wang; Jun Zhu; Zebo Huang; Huo Zhang; Xin Zhou; Wenfang Cheng; Yongqian Shu; Wei Zhu; Ping Liu
Journal:  Oncotarget       Date:  2017-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.